Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Genitourinary Cancer News

News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024

Stephanie Holland 

Stephanie Holland 
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024

Stephanie Holland 

Stephanie Holland 
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology

Advertisement

News
FDA Approves Belzutifan for Patients With Advanced Renal Cell Carcinoma
01/23/2024

Grace Taylor

Grace Taylor
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to...
01/23/2024
Journal of Clinical Pathways
News
FDA Approves Enfortumab Vedotin-Ejfv With Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer
01/10/2024

Grace Taylor

Grace Taylor
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to...
01/10/2024
Journal of Clinical Pathways
News
Study Analyzes Cabozantinib Plus Nivolumab and Ipilimumab for Patients With aRCC Who Have IMDC Intermediate or Poor Risk Scores
03/30/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...
At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...
At the 2023 ASCO GU Cancers...
03/30/2023
Journal of Clinical Pathways

Advertisement

News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
News
Higher Health Care Resource Utilization, Rates of Mortality and Economic Burdens in Recurrence of Renal Cell Carcinoma
10/25/2022

Yvette C Terrie

Yvette C Terrie
Renal cell carcinoma (RCC) recurrence is correlated with a significant increase in mortality, health care resource utilization (HRU), and health care costs, emphasizing the substantial unmet need in patients with intermediate high-risk and...
Renal cell carcinoma (RCC) recurrence is correlated with a significant increase in mortality, health care resource utilization (HRU), and health care costs, emphasizing the substantial unmet need in patients with intermediate high-risk and...
Renal cell carcinoma (RCC)...
10/25/2022
Journal of Clinical Pathways
News
Personalizing First-Line Treatments for Metastatic Renal Cell Carcinoma
07/12/2022

Ellen Kurek

Ellen Kurek
Researchers detail current first-line treatment options for the management of metastatic renal cell carcinoma and propose a framework for optimal treatment selection.
Researchers detail current first-line treatment options for the management of metastatic renal cell carcinoma and propose a framework for optimal treatment selection.
Researchers detail current...
07/12/2022
Journal of Clinical Pathways

Advertisement

News
Preoperative Short-Term Radiotherapy Followed by Chemotherapy vs Standard Schedule of Long-Term Chemoradiotherapy for the Treatment of Locally Advanced Rectal Cancer
05/31/2022

Ellen Kurek

Ellen Kurek
Short-term radiotherapy with preoperative chemotherapy followed by surgery may be efficacious with acceptable toxicity and could be used as an alternative to chemoradiotherapy among patients with locally advanced rectal cancer.
Short-term radiotherapy with preoperative chemotherapy followed by surgery may be efficacious with acceptable toxicity and could be used as an alternative to chemoradiotherapy among patients with locally advanced rectal cancer.
Short-term radiotherapy with...
05/31/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use